scispace - formally typeset
M

Mario Acunzo

Researcher at Virginia Commonwealth University

Publications -  62
Citations -  3679

Mario Acunzo is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Cancer & microRNA. The author has an hindex of 26, co-authored 53 publications receiving 3048 citations. Previous affiliations of Mario Acunzo include University of Naples Federico II & Ohio State University.

Papers
More filters
Journal ArticleDOI

miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.

TL;DR: It is reported that miR-221&222 are overexpressed in aggressive non-small cell lung cancer and hepatocarcinoma cells, as compared with less invasive and/or normal lung and liver cells, and it is demonstrated that the MET oncogene is involved in miR+222 activation through the c-Jun transcription factor.
Journal ArticleDOI

MicroRNA and cancer--a brief overview.

TL;DR: How miRNAs can be used as biomarkers and as a novel therapeutic approach in cancer is explained and the role of mi RNAs in cancer development and drug resistance is discussed.
Journal ArticleDOI

Small non-coding RNA and cancer

TL;DR: An overview of the four large classes of small non-coding RNAs, namely, miRNA, piRNAs, snoRNA and the new class of tRNA-derived fragments are provided, highlighting their fundamental role in cancer and their potential as diagnostic and prognostic biomarkers.
Journal ArticleDOI

miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222

TL;DR: MiR-130a, expressed at low level in lung cancer cell lines, by targeting MET was able to reduce TRAIL resistance in NSCLC cells through the c-Jun-mediated downregulation of miR-221 and miR -222.
Journal ArticleDOI

MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation.

TL;DR: Elucidation of this undiscovered ERK1/2 pathway that regulates apoptosis and cell proliferation through miR-494 in NSCLC will greatly enhance the understanding of the mechanisms responsible for TRAIL resistance and will provide an additional arm for the development of anticancer therapies.